Informations générales (source: ClinicalTrials.gov)
Anti-inflammatory and Cardiac Effects of Esmolol in Septic Shock. ESMOSEPSIS Study (ESMOSEPSIS)
Interventional
Phase 2
Central Hospital, Nancy, France (Voir sur ClinicalTrials)
décembre 2013
juin 2017
29 juin 2024
Beta adrenergic system, over-activated in septic shock patients, is a key modulator of
the inflammatory response. Experimental works demonstrated that Esmolol, an highly
selective beta-1 blocker, reduces heart rate and regulates the inflammatory response. A
recent mono centric, double blind, randomized clinical work in septic shock patients has
shown that Esmolol administration is safe and reduces effectively heart rate. However
there are only sparse data on 1) regional and micro-circulation, 2) inflammation
modulation in human resuscitated septic shock patients treated by esmolol.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHU de Nancy - 54511 - Nancy - France | Bruno Levy, MD PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- septic shock patients following the definition of the Surviving Sepsis Campaign
- femoral and central venous catheters for thermodilution monitoring
- fluid optimization
- with a cardiac index > 3 l/min/m2
- Heart Rate >100 /min
- septic shock patients following the definition of the Surviving Sepsis Campaign
- femoral and central venous catheters for thermodilution monitoring
- fluid optimization
- with a cardiac index > 3 l/min/m2
- Heart Rate >100 /min
- Cardiogenic shock
- Bradycardia
- History of Severe Asthma
- Indications against esmolol